Description

Overview

Cagrilintide is a long-acting analog of amylin, a pancreatic peptide hormone involved in meal-related satiety and energy-balance signaling. It has been developed for once-weekly clinical research and has been studied both alone and in combination with semaglutide. Unlike GLP-1 receptor agonists, cagrilintide works primarily through amylin/calcitonin-receptor-family signaling. Clinical studies have evaluated appetite, body weight, tolerability, and combination strategies designed to engage complementary metabolic pathways.

How It Works

• Amylin-receptor signaling: Cagrilintide activates amylin-receptor pathways involved in satiation and meal termination.
• Central appetite regulation: Amylin signaling influences brain regions involved in food intake and energy balance.
• Gastric and metabolic effects: Research has evaluated effects on gastric emptying and post-meal metabolic regulation.

Research Areas

• Satiety and appetite signaling
• Body-weight research
• Combination incretin/amylin research
• Metabolic regulation

Research / Study Context

• Phase 2 obesity research: Randomized human studies have evaluated multiple cagrilintide doses against placebo and active comparators.
• Combination studies: Cagrilintide has been studied with semaglutide to evaluate complementary amylin and GLP-1 pathways.

Key Research Findings

• Human trials demonstrate pharmacologic activity on appetite and body-weight endpoints.
• The compound remains investigational as a standalone research material.
• Combination research is a major area of ongoing development.

Related Research

• Semaglutide
• Tirzepatide
• Retatrutide

Scientific Reference Starter Set

• Peptide Education Hub: Cagrilintide profile/index
• PubMed search: cagrilintide obesity phase 2
• ClinicalTrials.gov search: cagrilintide